Parkman Healthcare Partners LLC 89bio, Inc. Transaction History

Parkman Healthcare Partners LLC

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$8.13 - $13.77 $321,533 - $544,589	-39,549 Reduced 18.02%	179,899 $2.09 Million
Q4 2023 Feb 14, 2024	SELL	$6.66 - $16.03 $959,739 - $2.31 Million	-144,105 Reduced 39.64%	219,448 $2.45 Million
Q3 2023 Nov 14, 2023	BUY	$15.06 - $19.41 $221,050 - $284,899	14,678 Added 4.21%	363,553 $5.61 Million
Q2 2023 Aug 11, 2023	BUY	$14.15 - $22.03 $1.44 Million - $2.25 Million	101,919 Added 41.27%	348,875 $6.61 Million
Q1 2023 May 12, 2023	SELL	$10.48 - $16.94 $900,483 - $1.46 Million	-85,924 Reduced 25.81%	246,956 $3.76 Million
Q4 2022 Feb 13, 2023	BUY	$5.52 - $12.73 $595,497 - $1.37 Million	107,880 Added 47.95%	332,880 $4.24 Million
Q3 2022 Nov 14, 2022	BUY	$3.02 - $7.0 $679,500 - $1.58 Million	225,000 New	225,000 $1.3 Million
Q1 2022 May 13, 2022	SELL	$3.45 - $14.99 $524,738 - $2.28 Million	-152,098 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$11.15 - $19.66 $69,687 - $122,875	6,250 Added 4.29%	152,098 $1.99 Million
Q3 2021 Nov 12, 2021	BUY	$14.91 - $21.31 $149,100 - $213,100	10,000 Added 7.36%	145,848 $2.86 Million
Q2 2021 Aug 13, 2021	BUY	$17.42 - $28.0 $586,792 - $943,180	33,685 Added 32.97%	135,848 $2.54 Million
Q1 2021 May 14, 2021	BUY	$20.22 - $26.73 $111,007 - $146,747	5,490 Added 5.68%	102,163 $2.42 Million
Q4 2020 Feb 12, 2021	SELL	$23.16 - $28.08 $308,653 - $374,222	-13,327 Reduced 12.12%	96,673 $2.36 Million
Q3 2020 Nov 13, 2020	BUY	$24.34 - $38.82 $2.68 Million - $4.27 Million	110,000 New	110,000 $2.82 Million

163

108M

73.6K

1.19M

Ticker ETNB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,484,500
Market Cap $417M
Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...

Get notified when there are updates to the investment portfolio of Parkman Healthcare Partners LLC, based on Form 13F filings with the SEC.

Stay updated on Parkman Healthcare Partners LLC with notifications on news.